Prostate-Specific Antigen Kinetics in Clinical Decision-Making During Active Surveillance for Early Prostate Cancer—A Review

Bergh, Roderick C.N. van den; Roemeling, Stijn; Roobol, Monique J.; Wolters, Tineke; Schröder, Fritz H.; Bangma, Chris H.

doi:10.1016/j.eururo.2008.06.040

Cited by 51 publications

(37 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding that plasma folate is associated with an increased risk of exceeding a PSAV threshold of 2 ng/mL/y provides tentative evidence to support this hypothesis. This PSAV threshold has been consistently associated with adverse posttreatment outcomes, including prostate cancer mortality (15). Most notably, D'Amico et al (12) reported a 10-fold increase in the odds of dying within 10 years of radical prostatectomy, based on PSAV estimated from measurements taken during the 12 months before diagnosis and surgery.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Associations of Folate, Vitamin B12, Homocysteine, and Folate-Pathway Polymorphisms with Prostate-Specific Antigen Velocity in Men with Localized Prostate Cancer

Collin

Metcalfe

Refsum

et al. 2010

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Vitamin B 12 , holo-haptocorrin, and the folate-pathway single-nucleotide polymorphisms MTR 2756A>G and SHMT1 1420C>T have been associated with an increased risk of prostate cancer. We investigated whether these and other elements of folate metabolism were associated with prostate-specific antigen (PSA) velocity (PSAV) as a proxy measure of prostate cancer progression in men with localized prostate cancer.Methods: We measured plasma folate, B 12 , holo-haptocorrin, holo-transcobalamin, total transcobalamin, and total homocysteine at diagnosis in 424 men (ages 45-70 years) with localized prostate cancer in a U.K.-wide population-based cohort. Thirteen folate-pathway single-nucleotide polymorphisms were genotyped for 311 of these men. Postdiagnosis PSAV (continuous measure and with a threshold set a priori at 2 ng/mL/y) was estimated from repeat PSA measurements.Results: Median follow-up time was 2.5 (range, 0.8-5.6) years. Vitamin B 12 , holo-haptocorrin, holotranscobalamin, total transcobalamin, and total homocysteine were not associated with postdiagnosis PSAV. Folate was associated with an increased risk of PSAV >2 ng/mL/y [odds ratio (OR) per unit increase in log e concentration, 1.57; 95% confidence interval (95% CI), 0.98-2.51; P = 0.06]. MTRR 66A>G (rs1801394) was associated with a reduced risk (recessive model OR, 0.33; 95% CI, 0.11-0.97; P = 0.04), and SHMT1 1420C>T (rs1979277) with an increased risk (per-allele OR, 1.49; 95% CI, 0.93-2.37; P = 0.09) of PSAV >2 ng/mL/y.Conclusions: We found weak evidence that higher folate levels may be associated with faster progression of localized prostate cancer.Impact: Long-term follow-up is needed to test associations with metastases and mortality, and the observed genetic effects require replication. Cancer Epidemiol Biomarkers Prev; 19(11); 2833-8. ©2010 AACR.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Although they are consistently associated with adverse outcomes (for pretreatment PSA kinetics: mortality, relapse, and pathologic stage; for active monitoring PSA kinetics: mortality and progression; ref. 15), we would need to follow up our cohort for a longer period (5-10 years) to determine their associations with clinical outcomes.…”

Section: Discussionmentioning

confidence: 99%

Associations of Folate, Vitamin B12, Homocysteine, and Folate-Pathway Polymorphisms with Prostate-Specific Antigen Velocity in Men with Localized Prostate Cancer

Collin

Metcalfe

Refsum

et al. 2010

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Different methods of calculating PSAve and PSAdt are available, with small differences in predictive value of the PSA derivative values obtained [12].…”

Section: Psa Kineticsmentioning

confidence: 99%

Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy

Schillaci

Calabria

Tavolozza

et al. 2012

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Active surveillance appears to be safe, as demonstrated in 7 studies. [45][46][47][48][49][50][51] (Level 3 Evidence.) The total number of patients in these studies is 2365 with a median follow-up ranging from 22 to 73 months.…”

Section: Active Surveillancementioning

confidence: 99%

Prostate cancer screening: Canadian guidelines 2011

Izawa

Klotz

Siemens

et al. 2011

cuaj

View full text Add to dashboard Cite

A systematic literature search was conducted in the following electronic bibliographic databases: MEDLINE, including PreMedline (2004 to November 2010), EMBASE (2004 to Week 44, 2010 and the Cochrane Central Register of Controlled Trials (2010, 4th Quarter). This search was restricted to studies published in English.The search queries were based on a combination of exploded and non-exploded subject headings and free-text keywords. These terms included prostate cancer, prostatic neoplasms, prostate tumour, prostate-specific antigen (PSA), digital rectal examination (DRE), DRE, mass screening, screening test, early detection of cancer, cancer screening, screening, PSA, transrectal ultrasound (TRUS), TRUS, randomized, false-negative and false-positive; we used alternative word spellings and endings.The search strategy was modified for each database using database-specific thesaurus terms, syntax and search fields. We excluded case reports, editorials, news and letters. To identify additional relevant studies, we also examined bibliographies of the relevant articles and selected reviews.We compiled 1938 unique citations and, after removing the duplicates, 1036 citations were assessed for relevance. The screening process yielded 49 articles for a full-text review.

show abstract

Prostate-Specific Antigen Kinetics in Clinical Decision-Making During Active Surveillance for Early Prostate Cancer—A Review

Cited by 51 publications

References 34 publications

Associations of Folate, Vitamin B12, Homocysteine, and Folate-Pathway Polymorphisms with Prostate-Specific Antigen Velocity in Men with Localized Prostate Cancer

Associations of Folate, Vitamin B12, Homocysteine, and Folate-Pathway Polymorphisms with Prostate-Specific Antigen Velocity in Men with Localized Prostate Cancer

Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy

Prostate cancer screening: Canadian guidelines 2011

Contact Info

Product

Resources

About